Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1994-04-26
1998-12-29
Smith, Lynette F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4241841, 4242041, 4242081, 530350, A61K 3900, A61K 3938, A61K 3921, C07K 100
Patent
active
058537252
ABSTRACT:
The present invention provides a non-infectious immunotherapeutic containing retroviral particles devoid of outer envelope proteins or containing selected antigens isolated from a retrovirus. In one aspect, the immunogen is useful for immunizing an individual previously infected by a retrovirus including HIV, so as to induce factors against progression of the infection. In another aspect, there is provided a method of rendering a viral immunogen non-infectious. The immunogen may also be used to produce antibodies for passive immunotherapy, alone or in conjunction with active immunotherapy, in individuals infected with a retrovirus, including HIV, preferably those individuals exhibiting low levels of antibodies to retroviral gene products other than the outer envelope.
REFERENCES:
patent: 4086134 (1978-04-01), Jarrett
patent: 4591505 (1986-05-01), Prince
patent: 4716102 (1987-12-01), Levy
Aldovini, et al, 1986, "Synthesis of the complete . . . " PNAS 83:6672-6676.
Haynes, 1993, "Scientific and Social Issues of . . . " Science 260:1279-1286.
Newmark, "Problems with AIDS Vaccines", Nature, 324:304-305 (1986).
Kennedy et al., "Anti-Idiotypic Antibody Vaccines for Type B Viral Hepatitis in Chimpanzees", Science, 232:220-223 (1986).
Cease et al., Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide: Proc. of the Natl. Acad. of Sci. 84:4249-4253 (1987).
Sternberg et al., Prediction of antigenic determinants and secondary structures of the major AIDS virus proteins:, FEBS Letters, 218-:231-237 (1987).
Marx et al., "Prevention of Simian Acquired Immune Deficiency Syndrome with a Formalin-Inactivated Type D Retrovirus Vaccine", Journal of Virology, 60:431-435 (1986).
Robert-Guroff et al., In Vitro Generation of an HTLV-III Variant by Neutralizing Antibody, J. of Immunology, 137:3306-3309, Nov. 15, 1986.
Kennedy and Chanh, Perspectives on Developing Anti-idiotype-based Vaccines for Controlling HIV Infection, Gower Acad. J. Ltd, AIDS 1988 2:S119-S127 (1988).
Fischer, Therapeutic Uses of Intravenous Gammaglobulin for Pediatric Infections, Pediatric Clinics of North America, 35:517-533 (1988).
McClelland and Yap, Clinical Use of Immunoglobulins, Clinics in Haematology 13:39-69 (1984).
Defendi and Jensen, Oncogenicity by DNA Tumor Viruses: Enhancement after Ultraviolet and Cobalt-60 Radiations, Science, 157:703-705 (1967).
Stiehm, Standard and Special Human Immune Serum Globulins as Therapeutic Agents, Pediatrics, 63:301-319 (1979).
Chan et al. "Induction of anti-HIV neutralizing antibodies by synthetic peptides", The EMBO Journal, 5:3065-3071 (1986).
Baum, "The search for vaccines", Chem. & Engr. News, 65:27-34 (1987).
Marx, "Making Antibodies without the Antigens", Science, 228:162-165 (1985).
Larue et al., "Suitable hollow fiber immunobioreactors for specific ex vivo removal of antibodies and antigens from plasma" Chem. Abstracts vol. 103, No. 25, Dec. 23, 1985, abstract No. 212882j.
Zagury et al., Nature 326:249-250 (1987).
Koff et al., Science 241:426-432 (1988).
Reed et al., J. Cell. Biochem. Suppl. 10A, p. 224, Abs. #D131 (Jan.-Feb. 1986).
Kramer et al., Science 231:1580-1584 (1986).
Salk, Nature 327:473-476 (1987).
Quinnan et al., Transfusion 26(3):481-483 (1986).
Fauci, Proc. Natl. Acad. Sci. USA 83:9278-9283 (1986).
Chang et al., Nature 315:151-154 (1985).
Sarngadharan, Cancer Res. (Supplemental) 45:4574-4577 (1985).
Carlo Dennis J.
Salk Jonas
Smith Lynette F.
The Immune Response Corporation
LandOfFree
Prevention and treatment of retroviral disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of retroviral disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of retroviral disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1421614